ObsEva Gives Up On IVF Drug As Phase III Study Fails
Confirmatory Trial Dashes Hopes Of Improved Ongoing Pregnancy Rate
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.
You may also be interested in...
AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is expected to be a competitive market.
Despite many improvements in the last 25 years, there continue to be serious unmet medical needs in the area of reproductive health. ObsEva SA, a clinical-stage biopharmaceutical company based in Geneva, Switzerland, aims to address some of those needs with novel oral drugs for three highly prevalent reproductive health-related challenges: endometriosis, pre-term labor, and repeated implantation failure in women undergoing in vitro fertilization.
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.